Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
Review
[키워드] ABG, Atrial blood gas
Analysis
Arbidol
assigned
Chest CT scans
Clinical improvement
clinical trial
Committee
conducted
Control
control group
control groups
COVID-19
COVID-2019, Coronavirus Disease 2019
Cox regression model
dose
effective
Effectiveness
Efficacy
Ethics
evaluate
GCS, Glasgow Coma Scale
hazard
Hospitalized
hospitalized patient
HR, hazard ratio
ICU, Intensive care unit
Infection
injection
Intervention
intervention group
ITT population
legally authorized representatives
LFT, liver function test
median
Medical Sciences
moderate
moderate-severe
Mortality
non-ICU patient
Open-label
participant
Patient
positive
positive RT-PCR
Prognosis
Randomized
randomized clinical trial
Randomly
Ratio
receive
Registered
Result
SARS-CoV-2
SARS-CoV-2, severe acute respiratory syndrome coronavirus2
severe COVID-19
Severe patient
single-center
statistically significant
statistically significant difference
Subcutaneous
time
treat
treated
Treatment
treatment group
Trial
TTCI
TTCI, Time to clinical improvement
two group
umifenovir
university
VBG, Venous blood gas
[DOI] 10.1016/j.intimp.2021.107969 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.intimp.2021.107969 PMC 바로가기 [Article Type] Review